There was a Oxaliplatin price significant difference in survival between the groups

(P<0.001). 75% of patients with DPAM were projected to survive to 5 years and 71% to 10 years (median survival not reached). In the PMCA group, 29% were alive at 5-year, with a median survival of 43 months. In the PMCA-I/D group, 5- and 10-year survivals were 90% and 90% respectively (median survival not reached). Figure 1 Survival by Histopathology Patients who were CA 19-9 negative had a better survival than those who were seropositive. The 5-year survivals were 90% and 46% respectively (P<0.001, Figure 2A). There was Inhibitors,research,lifescience,medical no significant difference in survival between patients based on CEA or CA-125 positivity, P=0.116 and Inhibitors,research,lifescience,medical P=0.128 respectively. Figure 2 A. Overall Survival by CA 19-9 Positivity (Entire Cohort); B. Survival Stratified by 4 CA 19-9 Subgroups (Entire Cohort) The impact of CA 19-9 on survival was further delineated when the cohort was split into 4 subgroups: CA 19-9 ≤40 U/mL, 41-100 U/mL, 101-1,000 U/mL and >1,000 U/mL to determine if the absolute level of CA 19-9 was of consequence. 90% of patients with CA 19-9 ≤40 U/mL were alive at 5 years. Patients with CA 19-9 ranging between 41-100 U/mL and 101-1,000 U/mL had a 5-year survival of 67% Inhibitors,research,lifescience,medical and 54% respectively. In contrast, the 5-year survival of patients with CA 19-9 >1,000 U/mL was 12%. (P<0.001, Figure 2B). In

these 4 subgroups, CA 19-9 levels were found to be associated with histopathological subtypes (P=0.033) and PCI (P=0.025, r=0.170). There was no significant relationship between CA 19-9 and CC-score (P=0.126). Survival outcomes for DPAM and PMCA-I/D subtypes There was a disparity in survival between patients who were Inhibitors,research,lifescience,medical CA 19-9 positive and those in the normal range. 5-year survivals for CA 19-9 negative and CA 19-9 positive patients were 90% and 58% respectively (P<0.001, Figure 3A). Figure 3 A. Survival by CA 19-9 Positivity (DPAM/PMCA-I/D); B. Overall Survival (DPAM/PMCA-I/D)-4 Inhibitors,research,lifescience,medical Subgroups This group was then further split into 4 subgroups as above; CA 19-9 ≤40 U/mL, 40-100 U/mL, 100-1,000 U/mL and >1,000 U/mL. In patients

with CA 19-9 >1,000 U/mL, the actuarial 5-year survival Selleck CDK inhibitor was 23%. This was in contrast to patients with CA 19-9 ≤100 U/mL, where the 5-year survival was more than 90% (P<0.001, Figure 3B). 100% of CEA-negative patients survived at 5 years, as opposed to 73% of CEA positive patients. The difference was not statistically significant (P=0.062). CA-125 positivity had no significant impact on survival (P=0.233). Other variables found to have an adverse effect on overall survival in the univariate analyses were CC-score 2/3 (P<0.001), PCI >25 (P<0.001) and male gender (P=0.017). Results from the Cox regression model are displayed in Table 2. Only CA 19-9 positivity was found to be an independent prognostic factor for poor survival (P=0.